JP2018533375A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533375A5
JP2018533375A5 JP2018542995A JP2018542995A JP2018533375A5 JP 2018533375 A5 JP2018533375 A5 JP 2018533375A5 JP 2018542995 A JP2018542995 A JP 2018542995A JP 2018542995 A JP2018542995 A JP 2018542995A JP 2018533375 A5 JP2018533375 A5 JP 2018533375A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
cas9 molecule
targeting domain
gene
hsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018542995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533375A (ja
JP7408284B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059502 external-priority patent/WO2017075475A1/en
Publication of JP2018533375A publication Critical patent/JP2018533375A/ja
Publication of JP2018533375A5 publication Critical patent/JP2018533375A5/ja
Priority to JP2022007688A priority Critical patent/JP2022068156A/ja
Priority to JP2023206552A priority patent/JP2024055867A/ja
Application granted granted Critical
Publication of JP7408284B2 publication Critical patent/JP7408284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018542995A 2015-10-30 2016-10-28 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物 Active JP7408284B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022007688A JP2022068156A (ja) 2015-10-30 2022-01-21 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物
JP2023206552A JP2024055867A (ja) 2015-10-30 2023-12-07 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562249159P 2015-10-30 2015-10-30
US201562249071P 2015-10-30 2015-10-30
US62/249,071 2015-10-30
US62/249,159 2015-10-30
PCT/US2016/059502 WO2017075475A1 (en) 2015-10-30 2016-10-28 Crispr/cas-related methods and compositions for treating herpes simplex virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022007688A Division JP2022068156A (ja) 2015-10-30 2022-01-21 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物

Publications (3)

Publication Number Publication Date
JP2018533375A JP2018533375A (ja) 2018-11-15
JP2018533375A5 true JP2018533375A5 (enExample) 2019-12-05
JP7408284B2 JP7408284B2 (ja) 2024-01-05

Family

ID=57321423

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018542995A Active JP7408284B2 (ja) 2015-10-30 2016-10-28 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物
JP2022007688A Withdrawn JP2022068156A (ja) 2015-10-30 2022-01-21 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物
JP2023206552A Pending JP2024055867A (ja) 2015-10-30 2023-12-07 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022007688A Withdrawn JP2022068156A (ja) 2015-10-30 2022-01-21 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物
JP2023206552A Pending JP2024055867A (ja) 2015-10-30 2023-12-07 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物

Country Status (7)

Country Link
US (2) US11001844B2 (enExample)
EP (1) EP3368670A1 (enExample)
JP (3) JP7408284B2 (enExample)
CN (2) CN109312338B (enExample)
AU (3) AU2016343991B2 (enExample)
CA (1) CA3001711A1 (enExample)
WO (1) WO2017075475A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
MA41349A (fr) * 2015-01-14 2017-11-21 Univ Temple Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
EP3532616A1 (en) 2016-10-28 2019-09-04 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12359223B2 (en) 2018-01-30 2025-07-15 Editas Medicine, Inc. Systems and methods for modulating chromosomal rearrangements
EP3746556A1 (en) * 2018-02-01 2020-12-09 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus (hsv) related keratitis
PL3765615T3 (pl) 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020055941A1 (en) * 2018-09-13 2020-03-19 Excision Biotherapeutics, Inc. Compositions and methods for excision with single grna
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3918071A1 (en) * 2019-02-01 2021-12-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions targeting virus genomes
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND USES THEREOF
AU2021232005A1 (en) * 2020-03-04 2022-09-29 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12630846B2 (en) * 2020-06-05 2026-05-19 The Regents Of The University Of Michigan Type I-C CRISPR system from Neisseria lactamica and methods of use
EP4179085A1 (en) * 2020-07-07 2023-05-17 Oriengene Biotechnology Ltd Guide rna for hsv-1 gene editing and method thereof
WO2022071974A1 (en) * 2020-10-02 2022-04-07 Temple University - Of The Commonwealth System Of Higher Education Rna guided eradication of herpes simplex type i and other related human herpesviruses
AU2022216614B2 (en) 2021-02-05 2026-03-05 Christiana Care Gene Editing Institute, Inc. Methods of and compositions for reducing gene expression and/or activity
EP4359425B1 (en) 2021-06-21 2026-08-05 Juvena Therapeutics, Inc. Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury
WO2024113302A1 (zh) * 2022-12-01 2024-06-06 深圳先进技术研究院 靶向HSV必需基因的gRNA、CRISPR/Cas基因编辑系统、递送系统及应用
CN116121271B (zh) * 2022-12-21 2025-05-09 四川农业大学 多杀性巴氏杆菌arcA基因及其应用
CN116270570A (zh) * 2023-02-27 2023-06-23 南方医科大学 CaMKP抑制剂在制备治疗疱疹病毒感染的药物中的用途
US12227748B1 (en) * 2024-04-25 2025-02-18 King Saud University Aptamers for binding to a membrane-based lipid

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
TR200201047T2 (tr) 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
US8481506B2 (en) * 2006-12-05 2013-07-09 Rosetta Genomics, Ltd. Nucleic acids involved in viral infection
US8153773B2 (en) 2007-06-19 2012-04-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2013059475A1 (en) 2011-10-18 2013-04-25 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
PT2931898E (pt) * 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
CN111218447B (zh) * 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
CN105899658B (zh) 2013-12-12 2020-02-18 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
WO2015126927A2 (en) * 2014-02-18 2015-08-27 Duke University Compositions for the inactivation of virus replication and methods of making and using the same
CA2943622A1 (en) * 2014-03-25 2015-10-01 Editas Medicine Inc. Crispr/cas-related methods and compositions for treating hiv infection and aids
WO2015153791A1 (en) * 2014-04-01 2015-10-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
WO2015153789A1 (en) * 2014-04-01 2015-10-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
WO2015153889A2 (en) * 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
SG11201608701QA (en) * 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
EP3169776B1 (en) 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation
US10071098B2 (en) * 2014-09-26 2018-09-11 Drexel University Compositions useful for treating herpes simplex labialis and/or herpes esophagitis, and methods using same
MA41349A (fr) * 2015-01-14 2017-11-21 Univ Temple Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
CA2981508A1 (en) 2015-04-01 2016-10-06 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
US9963719B1 (en) * 2016-12-05 2018-05-08 Editas Medicine, Inc. Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA

Similar Documents

Publication Publication Date Title
US12431216B2 (en) Methods for identifying class 2 crispr-cas systems
Gentile et al. More evidence of collusion: a new prophage-mediated viral defense system encoded by mycobacteriophage Sbash
Tsai et al. Complete genome sequence of the grouper iridovirus and comparison of genomic organization with those of other iridoviruses
CN103088008B (zh) 胞苷脱氨酶及其编码基因和它们的应用
EP3178935B1 (en) Genome editing using campylobacter jejuni crispr/cas system-derived rgen
JP2018534950A5 (enExample)
JP2022546608A5 (enExample)
JP2019115348A5 (enExample)
Mei et al. The C4 protein encoded by tomato leaf curl Yunnan virus reverses transcriptional gene silencing by interacting with NbDRM2 and impairing its DNA-binding ability
JP2016501532A5 (enExample)
JP2016165307A5 (enExample)
JPH11253177A5 (enExample)
CN102703424B (zh) 一种重组工程介导的大肠杆菌基因组点突变的方法
JP2016512960A5 (enExample)
CN114144519B (zh) 单碱基置换蛋白以及包含其的组合物
Stary et al. Simian virus 40 (SV40) large T antigen-dependent amplification of an Epstein-Barr virus-SV40 hybrid shuttle vector integrated into the human HeLa cell genome
KR20160050069A (ko) Cas9 변이체 및 그의 용도
Walter et al. Viral gene drive in herpesviruses
CN110835632A (zh) 新型碱基转换编辑系统用于基因治疗的应用
Chevanne et al. WD-repeat instability and diversification of the Podospora anserina hnwd non-self recognition gene family
JP7489112B2 (ja) Crisprタイプi-dシステムを利用した標的配列改変技術
Guo et al. Highly efficient CRISPR/Cas9-mediated homologous recombination promotes the rapid generation of bacterial artificial chromosomes of pseudorabies virus
Chapon et al. Comprehensive mutagenesis of herpes simplex virus 1 genome identifies UL42 as an inhibitor of type I interferon induction
Ke et al. Divergent transcriptomic responses underlying the ranaviruses-amphibian interaction processes on interspecies infection of Chinese giant salamander
RU2019139045A (ru) Способы и композиции для модификации гена регулятора трансмембранной проводимости при кистозном фиброзе (cftr)